MET097 for Obesity
(VESPER-4 Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new once-weekly injection called MET097 to determine if it safely aids weight loss. It targets adults who are obese or overweight and have weight-related health issues such as high blood pressure, high cholesterol, sleep apnea, or heart problems, but not diabetes. Participants will receive one of three different doses of MET097 or a placebo (a shot with no active medication). The trial lasts for 84 weeks, with the main results assessed after 64 weeks. Those who have gained or lost more than 11 pounds recently or have diabetes are not eligible. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants a chance to contribute to the potential availability of a new weight-loss treatment.
Do I need to stop my current medications to join the trial?
The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research has shown that MET097, a weekly injection for obesity, is generally safe. Studies indicate that most people tolerate MET097 well. Importantly, no serious side effects related to the treatment have been reported, which is a positive sign for its safety.
Previous studies with MET097 demonstrated that it can help people lose weight without causing serious side effects. This suggests that the treatment is not only effective but also safe for those considering joining a trial. While every medication can have side effects, the results so far are promising for MET097.12345Why do researchers think this study treatment might be promising for obesity?
Unlike the standard treatments for obesity, which often include lifestyle changes, medications like orlistat, or surgical options, MET097 is a novel approach administered via subcutaneous injection. Researchers are particularly excited about MET097 because it may offer a new mechanism of action, potentially targeting pathways that existing medications do not. This could lead to more effective weight management with possibly fewer side effects. The excitement also stems from its potential to provide consistent, long-lasting results, which is a significant challenge in current obesity treatments.
What evidence suggests that MET097 might be an effective treatment for obesity?
Research has shown that MET097, a medication that controls appetite and blood sugar, leads to significant weight loss. One study found that participants lost an average of 7.5% of their body weight, and this weight loss persisted even after discontinuing the medication. Another study reported an 8.1% reduction in body weight after 36 days. These findings suggest that MET097 can effectively help individuals with obesity or overweight conditions lose weight and maintain it over time. Participants in this trial will receive one of three different doses of MET097 or a placebo to further evaluate its effectiveness.12467
Are You a Good Fit for This Trial?
This trial is for adults with obesity or overweight who also have hypertension, dyslipidemia, sleep apnea, or cardiovascular disease. Participants should not have diabetes, significant weight changes in the past 3 months, a history of certain thyroid cancers (MTC), genetic conditions like MEN-2, chronic pancreatitis or recent acute pancreatitis.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive once-weekly injectable MET097 or placebo for 64 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- MET097
Trial Overview
The study tests MET097's effectiveness and safety when injected once weekly into adults with obesity-related health issues over an 84-week period. The main results are measured at week 64 and secondary outcomes at week 84. A placebo group serves as a comparison to see if MET097 really works.
How Is the Trial Designed?
4
Treatment groups
Experimental Treatment
Placebo Group
Participants will receive MET097 administered subcutaneously
Participants will receive MET097 administered subcutaneously
Participants will receive MET097 administered subcutaneously
Once-weekly placebo administered via subcutaneous injection
Find a Clinic Near You
Who Is Running the Clinical Trial?
Metsera
Lead Sponsor
Citations
1.
clinicaltrialvanguard.com
clinicaltrialvanguard.com/news/metsera-announces-positive-phase-1-results-for-met-097-an-ultra-long-acting-glp-1-agonist/Metsera Announces Positive Phase 1 Results for MET-097, ...
MET-097 demonstrated significant and sustained weight loss, achieving a 7.5% reduction in body weight. • The weight loss was maintained for at ...
2.
diabetesjournals.org
diabetesjournals.org/diabetes/article/74/Supplement_1/753-P/158835/753-P-Safety-Tolerability-PK-and-Efficacy-of753-P: Safety, Tolerability, PK, and Efficacy of MET097—A ...
Conclusion: MET097, an ultra-long acting GLP-1RA, results in significant weight loss sustained 8 wks post-treatment. Ongoing Ph2 studies will ...
Efficacy and Safety of MET097 Once-Weekly in People ...
This study investigates the efficacy and safety of once weekly injectable MET097 in adult participants with obesity or overweight with weight-related ...
4.
fiercebiotech.com
fiercebiotech.com/biotech/metseras-long-acting-glp-1-shot-linked-75-weight-loss-36-days-data-sparseMetsera GLP-1 data slice reveals 7.5% weight loss at 36 ...
For patients receiving Metsera's investigational injection at the 1.2-mg dose, weight loss continued after 36 days, with an 8.1% cumulative ...
Metsera's GLP-1 Receptor Agonist MET-097i | ADA 2025
Impressively, this effect was sustained even after the end of the dosing period, with a mean weight loss of 8.1% at Day 57 and 7.5% at Day 85.
NCT06712836 | A Phase 2b Study to Examine the Safety ...
This study is designed to test how well MET097, an active drug, works to treat individuals with obesity or overweight when compared to placebo. MET097 or ...
Long-acting GLP-1 lowers weight for adults with obesity
Adults receiving once-weekly 1.2 mg MET-097 lost 12.5% of their body weight at 28 weeks. An interim analysis of VESPER-3 revealed that ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.